Evolent Health price to sales ratio EVH

Market value divided by revenue over the last twelve months, since 2016.

Today, Oct 23, 2026: 0.3×
10-year median: 2.0×
Against its 10-year history: 9th; percentile: 0 is its lowest day, 100 its highest
10-year range: 0.1× to 6.7×
Peer median: 1.3×

Evolent Health's price to sales ratio is 0.3× as of Oct 23, 2026.

That is below its ten-year median of 2.0×, lower than on 91% of days in the last ten years.

Over that time it ranged from 0.1× in Mar 2026 to 6.7× in Nov 2016.

The median for 5 specialty Business Services stocks of a similar size is 1.3×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	0.3×	0.1×	0.4×
2025	0.2×	0.2×	0.6×
2024	1.7×	1.7×	2.2×
2023	2.1×	1.7×	3.0×
2022	2.3×	2.0×	3.3×
2021	2.7×	1.5×	3.1×
2020	1.4×	0.5×	1.4×
2019	0.9×	0.8×	3.0×
2018	3.0×	2.4×	4.4×
2017	2.3×	2.1×	6.6×
2016	4.7×	4.7×	10.3×

Against its peers

Companies in Specialty Business Services nearest Evolent Health's size, closest first, today.

Company	Price to sales ratio
EVHEvolent Health	0.3×
CRAICRA International	1.6×
DFINDonnelley Financial Solutions	1.8×
FCFranklin Covey	0.8×
VVXV2X	0.5×
MHMcGraw Hill	1.3×
Peer median	1.3×

Where Evolent Health ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Evolent Health

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.